Aldeyra The Total Assets
Aldeyra The total assets. Based on the latest financial reports, Aldeyra The (ALDX) holds total assets worth $47.54 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Aldeyra The for the company's overall valuation and market capitalisation.
Total Assets of Aldeyra The (2011–2025)
Total assets of Aldeyra The from 2011 to 2025. This chart illustrates how Aldeyra The's total assets have evolved over time, based on quarterly financial data. See ALDX share price today for real-time trading data and today's change.
Aldeyra The - Asset Composition Analysis
Aldeyra The Total Assets Breakdown (December 2025)
Aldeyra The total assets breakdown as of December 2025. Aldeyra The's total assets of $47.54 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 97.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Aldeyra The's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Aldeyra The working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aldeyra The's current assets represent 99.6% of total assets in 2025, an increase from 98.6% in 2011.
- Cash Position: Cash and equivalents constituted 97.2% of total assets in 2025, up from 96.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aldeyra The Competitors by Total Assets
Key competitors of Aldeyra The based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Aldeyra The - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.91 | 2.86 | 20.66 |
| Quick Ratio | 4.91 | 2.86 | 30.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $37.72 Million | $55.03 Million | $234.83 Million |
Aldeyra The - Advanced Valuation Insights
This section examines the relationship between Aldeyra The's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -31.1% |
| Total Assets | $72.06 Million |
| Market Capitalization | $37.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aldeyra The's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aldeyra The's assets decreased by 31.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aldeyra The (2011–2025)
The table below shows the annual total assets of Aldeyra The from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $72.06 Million | -31.11% |
| 2024-12-31 | $104.61 Million | -29.48% |
| 2023-12-31 | $148.33 Million | -18.18% |
| 2022-12-31 | $181.29 Million | -22.24% |
| 2021-12-31 | $233.14 Million | +179.70% |
| 2020-12-31 | $83.35 Million | +10.37% |
| 2019-12-31 | $75.52 Million | -20.58% |
| 2018-12-31 | $95.09 Million | +115.26% |
| 2017-12-31 | $44.17 Million | +75.38% |
| 2016-12-31 | $25.19 Million | -10.70% |
| 2015-12-31 | $28.20 Million | +220.98% |
| 2014-12-31 | $8.79 Million | +134.75% |
| 2013-12-31 | $3.74 Million | +89.34% |
| 2012-12-31 | $1.98 Million | +663.61% |
| 2011-12-31 | $258.90K | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more